Randomized Trialhigh evidence
Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet (London, England)·November 9, 2026·PMID 43003106
Why it mattersCardiovascular safety is a critical regulatory and clinical concern for novel incretin-based therapies. This trial provides reassurance that survodutide does not increase major adverse cardiovascular events in a high-risk obese population, supporting its potential use in cardiometabolic management.

The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled